KZIA Stock News Today: Kazia Therapeutics Soars on Rare Cancer Response as Nasdaq Delisting Risk Looms
Kazia Therapeutics Limited (NASDAQ: KZIA) is back on traders’ radars today after unveiling a rare immune‑complete response in a patient with metastatic triple‑negative breast cancer (TNBC) – even as the micro‑cap oncology company discloses a fresh Nasdaq delisting warning and